|1.||Rejas, Javier: 4 articles (01/2011 - 05/2009)|
|2.||Pérez, Concepción: 4 articles (01/2011 - 05/2009)|
|3.||Navarro, Ana: 4 articles (01/2011 - 05/2009)|
|4.||Brandt, Christian: 3 articles (08/2014 - 11/2009)|
|5.||May, Theodor W: 3 articles (11/2013 - 12/2007)|
|6.||Dickenson, Anthony H: 3 articles (10/2011 - 11/2008)|
|7.||Saldaña, María T: 3 articles (01/2011 - 05/2009)|
|8.||Oulis, Panagiotis: 3 articles (01/2010 - 03/2008)|
|9.||Mandel, Francine S: 3 articles (07/2009 - 03/2009)|
|10.||Wu, Feng: 2 articles (05/2015 - 02/2014)|
02/01/2008 - "Thirty-nine patients (74%) improved after 8 weeks with a mean dose of 269.8 mg/day (range 150-600 mg/day) PGB: 13 (25%) experienced complete pain relief and 26 (49%) reported pain reduction > 50%, whereas 14 (26%) did not improve. "
08/01/2010 - "Comparison of the results observed in the two groups shows that patients in the PGB group achieved significantly greater pain reduction. "
08/01/2010 - "After 4 weeks (primary endpoint) a significant improvement in pain reduction was documented in both intention-to treat (ITT) analysis (PGB group, n = 85: mean pain score reduction of 3.53, SD 2.03, p < 0.001; non-PGB group, n = 102; mean pain score reduction of 2.83, SD 2.23, p < 0.001) and per-protocol (PP) analysis (PGB group, n = 79: mean pain score reduction 3.53 vs. 2.83, p < 0.05; non-PGB group, n = 81; 3.5 vs. 2.9, p < 0.05) compared to baseline. "
06/01/2010 - "After 12 weeks, significant improvements in pain, associated symptoms of anxiety, depression and sleep disturbances, general health; and level of disability were observed in the three groups, being significantly greater in PGB groups. "
01/01/2010 - "As compared with the non-PGB, both PGBm and PGBadd-on schedules showed a significantly greater reduction of pain severity (36.1%, 56.1%, and 49.6% reductions, respectively, P < 0.001 between groups) and consumption of resources. "
09/01/2005 - "PGB is highly efficacious as adjunctive therapy in patients with refractory partial seizures. "
01/01/2004 - "PGB, 150 mg/day and 600 mg/day, is highly effective and well-tolerated add-on therapy in patients with partial seizures."
10/01/2008 - "PGB was efficacious, resulting in a significant reduction in the median frequency of seizure days/week between baseline and treatment (1.38 vs 0.50, P=0.018). "
08/01/2014 - "Results from this trial did not demonstrate that PGB-CR is effective in reducing seizure frequency below that of placebo. "
08/01/2011 - "Add-on PGB benefited 50% of patients, but only 10% achieved 6 months' seizure freedom. "
|3.||Neuralgia (Stump Neuralgia)
07/01/2014 - "The antiallodynic action of PGB is likely dependent on the suppression of WDR neuron hyperexcitability in rats with neuropathic pain."
07/01/2014 - "To elucidate the mechanisms underlying the antiallodynic action of PGB in rats with neuropathic pain. "
02/22/2013 - "Thus, GBP and PGB may act as indirect antagonists of NMDAR, a mechanism that may contribute to the clinical effects of the drugs in neuropathic pain."
12/01/2012 - "One explanation for how GBP and PGB relieve neuropathic pain is that they bind selectively to the Ca(+2) -channel subunit α2-δ in muscle tissue and brain. "
10/01/2012 - "For the two years prior to admission, she had taken PGB to treat post-herpetic neuralgia. "
06/01/2001 - "Clinic records of 19 patients who were consecutively enrolled at a tertial referral epilepsy center in a randomized, double-blind and/or open add-on study with PGB were reviewed. "
06/01/1987 - "The results of this study indicate that PGB was not a potent antiepileptic drug in this population of persons with intractable epilepsy."
12/01/2009 - "A cohort of patients attending a tertiary referral centre for epilepsy was identified as having started taking PGB. "
11/01/2009 - "We evaluated the data of the first 105 patients treated with PGB at Bethel Epilepsy Centre, a tertiary referral centre for epilepsy. "
07/01/2009 - "We performed an audit on 96 consecutive patients (44 male) prescribed PGB for refractory epilepsy. "
|5.||Anxiety Disorders (Anxiety Disorder)
03/01/2010 - "Data were combined from six short-term, double-blind, placebo-controlled, fixed-dose trials of PGB in patients with generalized anxiety disorder (GAD). "
11/01/2013 - "To our knowledge, PGB has not been studied before in patients with epilepsy and comorbid anxiety disorder. "
01/01/2012 - "PGB must be recommended in adjunctive therapy of anxiety disorders in patients with partial epilepsy."
01/01/2012 - "SER and PGB demonstrated high efficacy and safety in treatment partial epilepsy comorbid with depressive and anxiety disorders. "
05/01/2009 - "The objective of the study was to evaluate the response of generalized anxiety disorder (GAD) patients with prominent gastrointestinal (GI) symptoms to pregabalin (PGB) treatment. "
|4.||Calcium Channels (Calcium Channel)
|6.||Prostaglandins F (PGF)
|8.||Anticonvulsants (Antiepileptic Drugs)